TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06624059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Cohort B1: participants will receive oral alectinib twice daily (BID) for up to 5 years.~Cohort B2: Participants will receive oral alectinib BID for 3 cycles (cycle length = 3 weeks) prior to surgery, and for up to 5 years after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Cohort B1: participants will receive oral alectinib twice daily (BID) for up to 5 years.~Cohort B2: Participants will receive oral alectinib BID for 3 cycles (cycle length = 3 weeks) prior to surgery, and for up to 5 years after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cohort B1: Participants will receive intravenous (IV) cisplatin on Day 1 of each cycle for up to 4 cycles (cycle length = 3 weeks).~Cohort B2: Participants will receive IV cisplatin on Day 1 of each cycle for up to 3 cycles (cycles length = 3 weeks) prior to surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cohort B1: Participants will receive intravenous (IV) cisplatin on Day 1 of each cycle for up to 4 cycles (cycle length = 3 weeks).~Cohort B2: Participants will receive IV cisplatin on Day 1 of each cycle for up to 3 cycles (cycles length = 3 weeks) prior to surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Cohort B1: Participants will receive IV carboplatin on Day 1 of each cycle for up to 4 cycles (cycle length = 3 weeks).~Cohort B2: Participants will receive IV carboplatin on Day 1 of each cycle for up to 3 cycles (cycle length = 3 weeks) prior to surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Cohort B1: Participants will receive IV carboplatin on Day 1 of each cycle for up to 4 cycles (cycle length = 3 weeks).~Cohort B2: Participants will receive IV carboplatin on Day 1 of each cycle for up to 3 cycles (cycle length = 3 weeks) prior to surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Cohort B1: Participants will receive IV pemetrexed on Day 1 of each cycle for up to 4 cycles (cycle length = 3 weeks).~Cohort B2: Participants will receive IV pemetrexed on Day 1 of each cycle for up to 3 cycles (cycle length = 3 weeks) prior to surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Cohort B1: Participants will receive IV pemetrexed on Day 1 of each cycle for up to 4 cycles (cycle length = 3 weeks).~Cohort B2: Participants will receive IV pemetrexed on Day 1 of each cycle for up to 3 cycles (cycle length = 3 weeks) prior to surgery.
Study: NCT04807777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib will be administered orally twice daily during the entirety of each 28-day cycle.
Study: NCT06615921

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study: NCT06683742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYP-1901
Description: Intravitreal Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept (2.0 mg)
Description: Intravitreal Injection
Study: NCT06693986

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Replicative Adenovirus Vector (RGDCRAdCOX2F)
Description: RGDCRAdcox2F (RGD) is a local product and is provided through this study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Replicative Adenovirus Vector (RGDCRAdCOX2F)
Description: RGDCRAdcox2F (RGD) is a local product and is provided through this study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Replicative Adenovirus Vector (RGDCRAdCOX2F)
Description: RGDCRAdcox2F (RGD) is a local product and is provided through this study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Replicative Adenovirus Vector (RGDCRAdCOX2F)
Description: RGDCRAdcox2F (RGD) is a local product and is provided through this study.
Study: NCT06689163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-1167 tablets
Description: HRS-1167 tablets
Study: NCT05646589

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Person-centred care transition support
Description: Person-centred dialogue intended to permeate all patient-provider communication, various pedagogical modes of information, a person-centred care and rehabilitation plan, and a bridging e-meeting to prepare patients for homecoming.for persons who are to be discharged from hospitals after stroke or TIA

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular care transition
Description: Regular care transitions, initiated by an electronic referral from hospital healthcare professionals to the receiving neurorehabilitation team
Study: NCT04932733

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: The elderly participants in the experimental group underwent a single session of 5-minute quadriceps isometric exercise. The participant was asked to take a rest of 10 minutes before performing the exercise. After that, the exercise was performed from a long-sitting position.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Young isometric exercise
Description: The young participants in the experimental group underwent a single session of 5-minute quadriceps isometric exercise. The participant was asked to take a rest of 10 minutes before performing the exercise. After that, the exercise was performed from a long-sitting position.
Study: NCT06689163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate tablets（II）
Description: Abiraterone Acetate tablets（II）
Study: NCT05863156

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Right side lying position
Description: In the study, 60 participants were placed in the right side lying position (intervention 1)
Study: NCT06689163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone Acetate tablets
Description: Prednisone Acetate tablets
Study: NCT06686628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlitelimab
Description: Pharmaceutical form: Injection solution Route of administration: SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Pharmaceutical form: Solution Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Pharmaceutical form: Tablet Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Pharmaceutical form: Tablet Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Pharmaceutical form: Capsule Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Pharmaceutical form: Tablet Route of administration: Oral
Study: NCT05863156

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Right side lying position
Description: In the study, 60 participants were placed in the right side lying position (intervention 1)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Right side lying position
Description: In the study, 60 participants were placed in the right side lying position (intervention 1)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Semi Fowler
Description: In the study, 60 participants in the semi-sitting position (intervention 2)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Semi Fowler
Description: In the study, 60 participants in the semi-sitting position (intervention 2)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Semi Fowler
Description: In the study, 60 participants in the semi-sitting position (intervention 2)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: left side lying position
Description: In the study, 120 participants in the left side lying position (control group).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: left side lying position
Description: In the study, 120 participants in the left side lying position (control group).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: left side lying position
Description: In the study, 120 participants in the left side lying position (control group).
Study: NCT04773093

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continous Intravenous Lidocaine Infusion
Description: Patient will recieve intravenous Lidocaine dose 1.5 mg/kg at the time of induction and after that will receive maintenance by continous intravenous Lidocaine infusion dose 2 mg/kg/hour until the completion of surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patient will recieve Placebo NaCl 0.9% continuous intravenous infusion until the completion of surgery
Study: NCT04780334

Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-19 RT-PCR
Description: Nasopharyngeal swabs for COVID-19 RT-PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-19 RT-PCR
Description: Nasopharyngeal swabs for COVID-19 RT-PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: Biosensor
Description: Portable and Connected Biosensor viral

Intervention type: DIAGNOSTIC_TEST
Intervention: Biosensor
Description: Portable and Connected Biosensor viral
Study: NCT06626789

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amygdala neurofeedback
Description: Real-time fMRI neurofeedback from amygdala's blood oxygenation level dependent (BOLD) signal + negative emotional picture viewing. Instruction to regulate feedback via down-regulation of one's emotional response.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sham neurofeedback
Description: Recorded neurofeedback from a different participant + negative emotional picture viewing. Instruction to regulate feedback via down-regulation of one's emotional response.
Study: NCT06701539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome bupivacaine group
Description: After standardized anesthesia induction, bilateral scalp nerve block (supprorbital nerve, auriculotemporal nerve, major occipital nerve, minor occipital nerve) was performed with liposome bupivacaine stock solution, and 1-2ml was injected into each block site.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine group
Description: After standardized anesthesia induction, bilateral scalp nerve block (supraorbital nerve, auriculotemporal nerve, major occipital nerve, minor occipital nerve) was administered with 0.5% ropivacaine, and 1-2ml was injected into each block site.
Study: NCT06620042

Intervention type: DRUG
Group type: OTHER
Intervention: Ketamine
Description: Open-label Ketamine

Intervention type: OTHER
Group type: OTHER
Intervention: Functional magnetic resonance imaging (fMRI)
Description: Functional magnetic resonance imaging (fMRI) of the brain
Study: NCT06471530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TE-8105 SAD Cohort 1
Description: Each participant will receive one dose of TE-8105 0.5 up to 1.5mg injection via subcutaneous (SC) injection into the abdomen administered on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TE-8105 SAD Cohort 3
Description: Each participant will receive one dose of TE-8105 1.5 mg or less than or equal to 2.5 mg injection via subcutaneous (SC) injection into the abdomen administered on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TE-8105 SAD Cohort 5 (Adaptive cohort)
Description: Each participant will receive one dose of TE-8105 less than or equal to 6 mg injection via subcutaneous (SC) injection into the abdomen administered on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TE-8105 MAD Cohort 1
Description: Each participant will receive 0.5mg up to 1.5mg of TE-8105 injection via SC injection into the abdomen on Day 1 and then once every 2 weeks for 5 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TE-8105 MAD Cohort 2
Description: Each participant will receive 9 doses of TE-8105 injection via SC injection into the abdomen starting from Day 1 every 2 weeks. Dose will be titrated up by 0.5mg every 4 weeks, with dose levels of 1.5mg (2 doses), 2.0 mg (2 doses), 2.5 mg (2 doses) and 3.0 mg (3 doses)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TE-8105 SAD Cohort 2
Description: Each participant will receive one dose of TE-8105 0.75mg injection via subcutaneous (SC) injection into the abdomen on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TE-8105 SAD Cohort 4
Description: Each participant will receive one dose of TE-8105 3 mg or less than or equal to 5 mg injection via subcutaneous (SC) injection into the abdomen administered on Day 1.
Study: NCT05582421

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Diclofenac Sodium
Description: intracanal medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Sodium
Description: intracanal medication
Study: NCT04808063

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prophylactic mesh implantation
Description: Use of an algorithm for prophylactic mesh implantation in high risk patients after emergency midline laparotomy.
Study: NCT04687917

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The facilitation, training, feedback, and consultation (FTFC) Strategy
Description: A multilevel implementation strategy that includes team-focused facilitation, as well as staff-focused training, feedback, and consultation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The facilitation, training, feedback, consultation, and pay-for-performance (FTFC+PFP) Strategy
Description: A multilevel implementation strategy that includes team-focused facilitation, as well as staff-focused training, feedback, consultation, and pay-for-performance.
Study: NCT06459453

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kaltenborn
Description: Per participant was randomized to receive low grade Kaltenborn manual mobilization(grade I).Any tightening of the connective tissues surrounding the joint (grade II) or oscillations followed by additional stretching (grade III).Kaltenborm mobilization is performed for wrist flexion,extension,radial and ulnar deviation.The duration of intervention will be 4 weeks,3 sessions per week, a total of 12 sessions will be given to the study participants. Each session will be last for 30 minutes .Conventional physical therapy will be given to the participants along with kaltenborn.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan
Description: Per participant gave concurrent application of sustained accessory mobilization applied by a therapist and an active physiological movement to end range applied by the patient. Mulligan mobilization is performed for wrist flexion and extension(in the form of fist)MCP joint flexion and extension,Thumb IC joint flexion and extension, abduction and adduction of fingers, The duration of intervention will be 4weeks,3 sessions per week ,a total of 12 sessions will be given to the study participants .Each session will last for 30 minutes. Conventional physical therapy will be given to the participants along with conventional physiotherapy.
Study: NCT05352464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical traction with EMG biofeedback
Description: Continuous traction for 15-20 minutes in sitting position on average at an angle of 15-25 degrees of cervical flexion or in the most pain-free position.~Ask the patient to assume sitting position on a comfortable chair. Place surface electrodes of EMG biofeedback at the level of C5-6 Para spinal muscles to pick up the activity of the muscles and convert it to vis-ual and auditory impulses produced from the device. Tell the patient to try to relax the tension of the neck muscles as much as he can by lowering the visual and auditory impulses from the device

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cervical traction and conventional physical therapy
Description: Continuous traction for 15-20 minutes in sitting position on average at an angle of 15-25 degrees of cervical flexion or in the most pain-free position
Study: NCT04831320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Supplied by Celgene Corporation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Supplied by Bristol-Myers Squibb
Study: NCT06684275

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsed Radiofrequency (PRF)
Description: Participants will receive pulsed radiofrequency (PRF) treatment targeting the trigeminal nerve to manage pain associated with trigeminal neuralgia. This non-ablative technique uses electrical pulses to modulate nerve function, aiming to provide pain relief without creating a thermal lesion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed and Thermal Radiofrequency (PRF + TRF)
Description: Participants will receive a combination of pulsed radiofrequency (PRF) and thermal radiofrequency (TRF) treatments targeting the trigeminal nerve. This approach combines the non-ablative effects of PRF with the thermal lesioning of TRF to provide long-term pain relief for trigeminal neuralgia.
Study: NCT04948099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIB1116
Description: VIB1116

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06722183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib orally administered
Description: Futibatinib will be administered 20mg orally, once daily, continously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab (i.v. 200mg)
Description: Tislelizumab (i.v. 200mg) will be administered on day 1 and day 22 of a 6-week cycle
Study: NCT06723301

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chatbot-base problem-solving skills training(PSST)
Description: The intervention incorporates eight sessions: Session 1 involves rapport building, understanding relevant personal and medical history, and introducing the Chatbot-based program and worksheet; Session 2 focuses on maintaining brightness and optimism when faced with a specific obstacle; Sessions 3-7 involve the continued application of problem-solving skills training(PSST) to identify problems and the promotion of problem-solving strategies and skills in vivo, including (a) identifying the problem, (b) determining the options, (c) evaluating and choosing the best option, (d) acting according to the best option, and (e) seeing if it works; and Session 8 involves a review of PSST principles and termination.
Study: NCT06733467

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stimulus properties: remembered feature
Description: The feature used to determine which stimulus feature to remember to will be varied across trials using a letter cue (M = remember-motion; C = remember-color; 0 = remember nothing)
Study: NCT06733584

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Culturally and Linguistically Responsive Pathways Parent-Mediated Intervention without Mutual Gaze
Description: Pathways-trained bilingual research clinicians will conduct 90-minute weekly coaching sessions with caregivers in the family's home or other convenient location. Caregivers will receive a written and audio version of the program manual which has been adapted to be culturally and linguistically responsive to the Hispanic community. Sessions will review information about social communication, social sensory routines, and using naturalistic developmental behavioral strategies. Interventionists will demonstrate intervention strategies and provide caregivers with feedback and self-reflection.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally and Linguistically Responsive Pathways Parent-Mediated Intervention
Description: Pathways-trained bilingual research clinicians will conduct 90-minute weekly coaching sessions with caregivers in the family's home or other convenient location. Caregivers will receive a written and audio version of the program manual which has been adapted to be culturally and linguistically responsive to the Hispanic community. Sessions will review information about social communication, infusing mutual gaze in social sensory routines, and using naturalistic developmental behavioral strategies. Interventionists will demonstrate intervention strategies and provide caregivers with feedback and self-reflection.
Study: NCT06483152

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metro Transit Pass
Description: A transit pass that enables riders to use the Minneapolis Metro Transit system that will paid for by the study for 6 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The current standard of care for Ryan White eligible clients is to receive two $10 bus cards a month from a case manager
Study: NCT06733753

Intervention type: PROCEDURE
Intervention: ultrasound-guided thermal ablation
Description: microwave ablation, radio frequency ablation, laser ablation
Study: NCT06729554

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education & Care in RARE
Description: Education \& Care in RARE (https://www.youtube.com/watch?v=R3fr-q-6JIw) is a short-term, structured, resource-oriented and child-friendly psychoeducation program for children and adolescents with rare diseases. It promotes knowledge and competence on rare diseases in children in order to reduce the psychosocial rare disease burden and to improve individual self-competence in managing the rare disease and to improve their quality of life. Education \& Care in RARE can be used for all pediatric rare diseases. This has the great advantage that users only need to be trained in the use of one program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education & Care in RARE
Description: Education \& Care in RARE (https://www.youtube.com/watch?v=R3fr-q-6JIw) is a short-term, structured, resource-oriented and child-friendly psychoeducation program for children and adolescents with rare diseases. It promotes knowledge and competence on rare diseases in children in order to reduce the psychosocial rare disease burden and to improve individual self-competence in managing the rare disease and to improve their quality of life. Education \& Care in RARE can be used for all pediatric rare diseases. This has the great advantage that users only need to be trained in the use of one program.